Natpara: Additional Phase III data

Additional data from the double-blind, dose-escalation, international Phase III REPLACE trial in 134 patients showed that once-daily Natpara produced significant increases in bone turnover markers at week 24 vs. baseline, while placebo produced no significant changes. Specifically, Natpara led to significant increases

Read the full 423 word article

How to gain access

Continue reading with a
two-week free trial.